ProQR doses first participant in Phase 1 trial of AX-0811

September 9, 2026 8:00 AM

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that the first participant has been dosed in a Phase 1 clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found